A 36 week randomized, double-blind, parallel group, multi-center, active-controlled, optional titration study comparing an aliskiren-based regimen to a ramipril-based regimen in patients greater than or equal to 65 years old with systolic essential hypertension.
Latest Information Update: 13 Jun 2011
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide; Ramipril
- Indications Hypertension; Isolated systolic hypertension
- Focus Therapeutic Use
- Acronyms AGELESS
- Sponsors Novartis
- 24 Dec 2009 Resuts published in the Journal of Human Hypertension.
- 21 Jul 2009 Actual end date (1 Feb 2008) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.